Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
Aydin Huseynov
Michael Behnes
Uzair Ansari
Stefan Baumann
Dirk Lossnitzer
Ibrahim El-Battrawy
Christian Fastner
Martin Borggrefe
Ibrahim Akin
1.First Department of Medicine,University Medical Centre Mannheim(UMM),University of Heidelberg,Mannheim,Germany2.First Department of Medicine,University Medical Centre Mannheim(UMM),University of Heidelberg,Mannheim,Germany3.First Department of Medicine,University Medical Centre Mannheim(UMM),University of Heidelberg,Mannheim,Germany4.First Department of Medicine,University Medical Centre Mannheim(UMM),University of Heidelberg,Mannheim,Germany5.First Department of Medicine,University Medical Centre Mannheim(UMM),University of Heidelberg,Mannheim,Germany6.First Department of Medicine,University Medical Centre Mannheim(UMM),University of Heidelberg,Mannheim,Germany7.First Department of Medicine,University Medical Centre Mannheim(UMM),University of Heidelberg,Mannheim,Germany8.First Department of Medicine,University Medical Centre Mannheim(UMM),University of Heidelberg,Mannheim,Germany9.First Department of Medicine,University Medical Centre Mannheim(UMM),University of Heidelberg,Mannheim,Germany
摘要：The COMBO stent(OrbusNeich Medical BV,the Neth-erlands) is a stainless-steel platforrn with the biodegradable abluminal coating containing antiproliferative sirolimus(5 mg/mm) and the lurninal stent surface covered with anti-CD-34 antibody.The CD-34 antibodies essentially capture endothelial progenitor cells resulting in rapid re-endothelia-lization of the treated segment.This characteristic was ini-tially demonstrated in in-vitro models,and its safety proven in the larger randornized clinical trials with dual therapy stents.[1-3]The REMEDEE(Randornized study to Evaluate the safety and effectiveness of an abluMinal sirolimus-coatED bio-Engineered StEnt) Trial was the first human trial comparing COMBO stents to the paclitaxel drug elut-ing stents(Taxus Liberte,Boston Scientific,Marlborough,Massachusetts).High initial procedural success,low revas-cularization rates,and low stent thrombosis rates were ob-served in all these patient populations.The trial protocol dictated a dual antiplatelet therapy(DAPT) for a duration of 6 months in elective cases and for 12 months in patients diagnosed with an acute coronary syndrome(ACS).
机标关键词：
论文发表日期：2019-11-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：4( 840-843 )
英文信息